Forbion Eyes Late-Stage Opportunities With New Fund
Venture Capital Firm Raises Initial €470m
Looking to take advantage of the cool reception private biotechs are receiving from the public markets, a leading European VC is targeting investments of up to €70m per deal in firms with undervalued late-stage assets.
